Wedbush analyst Michael Pachter downgraded Fitbit to Neutral from Outperform, as shares have reached his $6.50 price target with no new available information on the MedTech opportunity. In a research note to investors, Pachter says he thinks what is currently known about the MedTech opportunity is fully priced into Fitbit’s share price, and will step to the sidelines until he knows more.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.